## Interview Summary

Application No.

10/721,793

CORONA VILLEGAS ET AL.

Examiner

Anand U. Desai, Ph.D.

Applicant(s)

CORONA VILLEGAS ET AL.

1653

All participants (applicant, applicant's representative, PTC	personnel):
(1) <u>Anand U. Desai, Ph.D.</u> .	(3)
(2) Ms. Laura Vogel.	(4)
Date of Interview: 12 September 2006.	
Type: a)⊠ Telephonic b)□ Video Conference c)□ Personal [copy given to: 1)□ applicant	2) applicant's representative]
Exhibit shown or demonstration conducted: d) Yes If Yes, brief description:	e)⊠ No.
Claim(s) discussed: 3.	
Identification of prior art discussed: <u>Discussed the sequention</u> <u>115</u> .	ce search of the polypeptide represented as SEQ ID NO:
Agreement with respect to the claims f)☐ was reached.	g)□ was not reached. h)⊠ N/A.
how SEQ ID NO: 115 is a chemically distinct compound. In 112, 1st paragraph written description for isolated nucleic and NO: 115. Discussed how SEQ ID NO: 115 is drawn to an polypeptide.	n/election of SEQ ID NO: 115. Discussed MPEP 2434 and Discussed possible amendments to the claims. Discussed acid sequences having certain percent identity to SEQ ID isolated nucleic acid sequence and not an isolated diments which the examiner agreed would render the claims copy of the amendments that would render the claims ad.)
INTERVIEW. (See MPEP Section 713.04). If a reply to th GIVEN A NON-EXTENDABLE PERIOD OF THE LONGER	e last Office action has already been filed, APPLICANT IS OF ONE MONTH OR THIRTY DAYS FROM THIS FERVIEW SUMMARY FORM, WHICHEVER IS LATER, TO
Examiner Note: You must sign this form unless it is an	1

Attachment to a signed Office action.

Examiner's signature, if required